These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 23982384)

  • 1. JAMA patient page. Tamoxifen update.
    Sugerman DT
    JAMA; 2013 Aug; 310(8):866. PubMed ID: 23982384
    [No Abstract]   [Full Text] [Related]  

  • 2. New Insights Into Nonadherence With Adjuvant Endocrine Therapy Among Young Women With Breast Cancer.
    Rosenberg SM; Partridge AH
    J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26307642
    [No Abstract]   [Full Text] [Related]  

  • 3. Caring for the breast cancer survivor.
    Abdel-Razeq H
    Am J Med; 2011 Feb; 124(2):e11; author reply e13. PubMed ID: 21295181
    [No Abstract]   [Full Text] [Related]  

  • 4. [The Oxford meta-analysis of 2000: reflections and comments].
    Mustacchi G
    Tumori; 2005; 91(5):1-9. PubMed ID: 16459647
    [No Abstract]   [Full Text] [Related]  

  • 5. Current limits of knowledge in adjuvant and neoadjuvant endocrine therapy of breast cancer: the need for more clinical research.
    Hayward RL; Dixon JM
    Surg Oncol; 2003 Dec; 12(4):289-304. PubMed ID: 14998569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Timing is everything: order of administration of 5-aza 2' deoxycytidine, trichostatin A and tamoxifen changes estrogen receptor mRNA expression and cell sensitivity.
    Hostetter CL; Licata LA; Keen JC
    Cancer Lett; 2009 Mar; 275(2):178-84. PubMed ID: 19013015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The optimal duration of adjuvant therapy in breast cancer: what kind of evidence? Hormone therapy: what kind of evidence?].
    Angiolini C
    Suppl Tumori; 2004; 3(4):S75-6. PubMed ID: 15206219
    [No Abstract]   [Full Text] [Related]  

  • 8. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer.
    Owusu C; Buist DS; Field TS; Lash TL; Thwin SS; Geiger AM; Quinn VP; Frost F; Prout M; Yood MU; Wei F; Silliman RA
    J Clin Oncol; 2008 Feb; 26(4):549-55. PubMed ID: 18071188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen and the factor V Leiden mutation.
    Cuzick J
    J Natl Cancer Inst; 2010 Jul; 102(13):918-9. PubMed ID: 20554943
    [No Abstract]   [Full Text] [Related]  

  • 10. [The optimal duration of adjuvant therapy in breast cancer: what kind of evidence? Hormone therapy: the example of clinical studies].
    Giannessi PG
    Suppl Tumori; 2004; 3(4):S73-4. PubMed ID: 15206218
    [No Abstract]   [Full Text] [Related]  

  • 11. Multicenter phase II feasibility trial of high-dose tamoxifen in patients with refractory or relapsed multiple myeloma.
    Decaudin D; Etienne MC; De Cremoux P; Maciorowski Z; Vantelon JM; Voog E; Urien S; Tran-Perennou C; Renée N; Vielh P; Némati F; Pouillart P
    J Natl Cancer Inst; 2004 Apr; 96(8):636-7. PubMed ID: 15100346
    [No Abstract]   [Full Text] [Related]  

  • 12. Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial.
    Nordenskjöld B; Rosell J; Rutqvist LE; Malmström PO; Bergh J; Bengtsson NO; Hatschek T; Wallgren A; Carstensen J
    J Natl Cancer Inst; 2005 Nov; 97(21):1609-10. PubMed ID: 16264181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Refining the use of endocrine therapy for ductal carcinoma in situ.
    Morrow M
    J Clin Oncol; 2012 Apr; 30(12):1249-51. PubMed ID: 22393104
    [No Abstract]   [Full Text] [Related]  

  • 14. Anti-estrogens in the treatment of breast cancer: current status and future directions.
    Barker S
    Curr Opin Investig Drugs; 2003 Jun; 4(6):652-7. PubMed ID: 12901222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
    Kaufmann M; Rody A
    Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):146-54. PubMed ID: 16621229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does c-erbB2/HER2 overexpression predict adjuvant tamoxifen failure in patients with early breast cancer?
    Hu JC; Mokbel K
    Eur J Surg Oncol; 2001 Jun; 27(4):335-7. PubMed ID: 11417974
    [No Abstract]   [Full Text] [Related]  

  • 17. Breast cancer and duration of tamoxifen.
    Prescrire Int; 2015 Sep; 24(163):220. PubMed ID: 26417636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study.
    Dew JE; Wren BG; Eden JA
    Climacteric; 2002 Jun; 5(2):151-5. PubMed ID: 12051110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical evaluation of tamoxifen for advanced and recurrent breast cancer (author's transl)].
    Horumon To Rinsho; 1980 Apr; 28(4):425-36. PubMed ID: 7006865
    [No Abstract]   [Full Text] [Related]  

  • 20. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
    Jankowitz RC; McGuire KP; Davidson NE
    Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.